Hero Image
27 June 2025
Tokyo, Japan
Nordic Health Summit Japan 2025
Register now
Open until 20 June 2025

WHY JAPAN


Japan is a top-three healthcare market in the world, and home to many top pharma companies with an appetite for Nordic innovations.

Japan is an extremely large market – with 125 million people, it is the 3rd
largest healthcare market in the world, and home to some of the top global healthcare companies in the world. 

The country has a comprehensive universal healthcare system, and patients can freely choose their healthcare providers. Medical expenditures in Japan have increased by over 30% since 2000, and now constitute 11% of GDP. 

As pressing issues arise in the healthcare and life science industry, Japanese companies are keen on collaborating with overseas startups with cutting-edge solutions to boost innovation.

Examples of the strong track record of Japanese investment in the Nordic life science sector:


- Fujifilm USD 1.6 billion investment to expand CDMO business in Denmark.

- Eisai's investment in Sweden’s BioArctic led to the world’s first fully FDA approved fully approved Alzheimer’s drug in 2023. 

- Asahi Kasei Pharma acquired Calliditas Therapeutics in 2024 (USD 1.1 billion).  



Location
Life Science Innovation Network Japan (LINK-J) address:2F Nihonbashi IT building, 3-3-9 Nihonbashi Muromachi, Chuo-ku, Tokyo 103-0022 See map https://www.link-j.org/en/access/
Organised by
Meetings
Participants 92
Meetings 40
Participants
Japan 56
Sweden 22
Finland 9
Denmark 3
Norway 2
Total 92